智通财经APP获悉，据港交所2月9日披露，杭州糖吉医疗科技股份有限公司(简称：糖吉医疗)向港交所 主板递交上市申请书，工银国际、财通国际为其联席保荐人。 | 纂]項下的[编纂]數目 : [编纂]股H股(視乎[编纂] | | | --- | --- | | 行使與合向定) | | | [编纂]數目 | : [编纂]股H股(可予[编纂]) | | [编纂]數目 | : [编纂]股H股(可于编纂]及 | | 視乎[编纂]行使與否而定) | | | 最高[编纂] .. | 每股H股[编纂]港元,另加1.0%經紀冊金、 | | 0.0027%證監會交易微費、0.00015% | | | 會財局交易徵費及0.00565%香港聯交所 | | | 交易費(須於申請時以港元繳足, | | | 多織股款可予想還) | | | 面值 | : 每股H股人民幣0.10元 | | 【湯養】 | : [编纂] | | 聯席保薦人 ·[编纂] | | 公司简介 招股书披露，糖吉医疗是一家立足中国的医疗器械公司，专注于为代谢性疾病的治疗及全周期管理提供 创新解决方案。公司战略构建了涵盖肥胖及代谢性疾病治疗器械与适配器械及全周期管理产品的产品管 ...

Core Viewpoint - The company held its 43rd meeting of the 5th Board of Directors, where it approved two key proposals regarding equity transfer and participation in restructuring investment bidding [1][5]. Group 1: Equity Transfer Proposal - The company agreed to the transfer of 1% unpaid equity of its subsidiary, Shandong Buchang Guanyou Medical Equipment Co., Ltd., from shareholder Liu Anan to Zhu Binbin at a price of RMB 0, while waiving its right of first refusal [2][11]. - After the transfer, the company's ownership in Buchang Guanyou will remain at 90% [11][13]. - The transaction does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations, and does not require shareholder approval [11][12]. Group 2: Restructuring Investment Bidding Proposal - The company plans to participate in the bidding for restructuring investor qualifications to expand its presence in the traditional Chinese medicine sector, aligning with its strategic vision of becoming "China's Johnson & Johnson" [5][18]. - Due to the uncertainties and commercial confidentiality involved in this transaction, specific details will be disclosed after the bidding process concludes [5][18]. - The proposal was also approved by the Board's Strategic and Investment Committee before being presented to the Board [3][6].

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 12,700 shares on February 9, indicating a fluctuating interest from these investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 674,000 shares [1] - In the last twenty trading days, there were ten days of net reductions, with a cumulative net decrease of 769,000 shares [1] - Currently, southbound funds hold 41,477,300 shares of Chuangli Medical, accounting for 43.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. specializes in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Group 1 - The core point of the article is that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 60,000 shares on February 9, 2026, while experiencing a net reduction of 2.5329 million shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have increased their holdings in MicroPort Medical on 13 occasions, with a total net increase of 16.2003 million shares [1] - As of now, southbound funds hold 925 million shares of MicroPort Medical, accounting for 48.23% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on February 9, 2026, is 925 million, with a change of 60,000 shares, reflecting a change of 0.01% [2] - On February 6, 2026, there was a reduction of 1.5155 million shares, representing a decrease of 0.16% [2] - The company operates in the medical device sector, focusing on sales, production, research, and development through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, and surgical robotics [2]

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-003 深圳惠泰医疗器械股份有限公司 第三届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）第三届董事会第三次会议通知于2026年2月9日发出 并送达全体董事，全体董事同意豁免本次会议的提前通知时限要求。本次会议于2026年2月9日以现场结 合通讯方式召开，会议应到董事9人，实到董事9人，出席董事占应出席人数的100%。本次会议的召 集、召开及表决程序符合《中华人民共和国公司法》等有关法律、行政法规、规范性文件和《深圳惠泰 医疗器械股份有限公司章程》的规定，会议决议合法有效。经与会董事审议和表决，会议形成决议如 下： 一、审议通过《关于以集中竞价交易方式回购股份方案的议案》 董事会认为，本次回购公司股份方案设计合理，有利于维护广大投资者利益，增强投资者对公司的投资 信心，建立健全公司长效激励机制，促进公司健康可持续发展，全体董事一致同意该事项。 具体内容详见公司同日在上海证券交易所网站（ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603858 证券简称：步长制药 公告编号：2026-019 山东步长制药股份有限公司 关于拟放弃优先受让控股子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 公司控股子公司步长冠优股东刘安安拟将其所持有的步长冠优1%未实缴股权以人民币0元的价格转让 给朱彬彬。公司同意放弃优先受让权，交易完成后，公司持有步长冠优90%股权比例不变。 ● 本次交易未构成关联交易，亦未构成《上市公司重大资产重组管理办法》规定的重大资产重组。该事 项无须提交股东会审议批准。 ● 本次交易实施不存在重大法律障碍。 ● 本次交易事项未导致公司合并报表范围发生变化，亦不会对公司财务状况和经营成果产生重大不利影 响。 一、交易概述 山东步长冠优医疗器械有限公司（以下简称"步长冠优"）为山东步长制药股份有限公司（以下简称"公 司"）控股子公司，公司持有其90%股权，谢继辉持有其4%股权，何涛持有其2%股权，罗文清、于海 铭、魏齐文、刘安安各持有其1%股权。 公司于 ...

Core Viewpoint - Shenzhen Huitai Medical Equipment Co., Ltd. has approved a share repurchase plan to enhance investor confidence and establish a long-term incentive mechanism [1] Group 1: Share Repurchase Plan - The company plans to use its own funds to repurchase part of its A-shares through centralized bidding, with a total repurchase amount not less than RMB 150 million and not exceeding RMB 200 million [1] - The maximum repurchase price is set at RMB 315 per share, and the repurchase period is within 10 months from the board's approval date [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives, and if not fully transferred within three years, they will be legally canceled [1] Group 2: Financial Position - As of September 30, 2025, the company's total assets are approximately RMB 3.461 billion, and the net assets attributable to shareholders are about RMB 2.989 billion [1] - Based on the upper limit of the repurchase funds, the repurchase amount accounts for approximately 6.69% of the net assets [1] Group 3: Impact and Confidence - The company believes that the repurchase will not significantly impact its daily operations, finances, or future development, nor will it lead to a change in control or affect its listing status [1] - The decision is based on confidence in the industry outlook and the company's future development [1]

截至2026年2月9日收盘，振德医疗(603301)报收于80.69元，上涨10.01%，涨停，换手率1.76%，成交量 4.68万手，成交额3.73亿元。 资金流向方面，主力资金净流入7554.63万元，占总成交额20.25%；游资资金净流出4650.14万元，占总 成交额12.46%；散户资金净流出2904.49万元，占总成交额7.78%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自【交易信息汇总】：振德医疗2月9日涨停收盘，封单资金达1.95亿元，占其流通市值0.91%。 来自【交易信息汇总】：主力资金净流入7554.63万元，占总成交额20.25%，呈现明显吸筹迹象。 当日关注点 交易信息汇总 振德医疗2月9日涨停收盘，收盘价80.69元。该股于9点48分涨停，未打开涨停，截止收盘封单资金为 1.95亿元，占其流通市值0.91%。 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经讯，锦好医疗2月9日发布公告称，2025年，公司营业收入为3.08亿元，上年同期为1.86亿元，同比 上升65.26%。利润总额为1756万元，上年同期为475万元，同比上升270.03%。归属于上市公司股东的 净利润为1516万元，上年同期为598万元，同比上升153.62%。 （记者 曾健辉） ...

据港交所2月9日披露，杭州糖吉医疗科技股份有限公司(简称：糖吉医疗)向港交所主板递交上市申请书，工银国际、财通国际为其联席保荐人。招股书披 露，糖吉医疗是一家立足中国的医疗器械公司，专注于为代谢性疾病的治疗及全周期管理提供创新解决方案。公司战略构建了涵盖肥胖及代谢性疾病治疗器 械与适配器械及全周期管理产品的产品管线，所有产品均专注于代谢性疾病的治疗及管理，适应证包括超重、肥胖症、伴有肥胖的MASH及伴有肥胖的2型 糖尿病。 ...